Company Website:
http://www.zlk.com
NEW YORK -- (Business Wire)
Levi & Korsinsky, LLP announces it has commenced an investigation of
XBiotech Inc. (“XBiotech”) (NASDAQ:XBIT) concerning possible violations
of federal securities laws.
On April 20, 2017, XBiotech announced that the European Medicines Agency
(“EMA”) had rendered a negative trend vote after meeting with the
Company to discuss its marketing authorization application (“MAA”) for
XBiotech's candidate antibody for the treatment of colorectal cancer.
Then on May 18, 2017, XBiotech announced it had received a negative
opinion for its MAA. Then on June 9, 2017, XBiotech announced it had
discontinued a Phase 3 study for the treatment after the findings “were
not sufficient to meet efficacy or the threshold for continuation.” To
obtain additional information, go to:
http://www.zlkdocs.com/XBIT-Info-Request-Form-5678
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York,
Connecticut, California and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170918006504/en/
Contacts:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel:
212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com
Source: Levi & Korsinsky, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.